| Assay ID | Title | Year | Journal | Article |
|---|
| AID285824 | Cmax in healthy human plasma at 800 mg measured on day 1 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
| Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects. |
| AID263226 | Antiviral activity against HIV1 I50V in MT4 cells | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID396238 | Antiviral activity against HIV1 BaL in human PBMC assessed as blockade of reverse transcriptase activity | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID743915 | Dose-normalized AUC in rat at 0.25 mg/kg, iv co-administered with 4 mg/kg of ritonavir | 2013 | European journal of medicinal chemistry, May, Volume: 63 | Synthesis and pharmacokinetic profile of highly deuterated brecanavir analogs. |
| AID743920 | Plasma clearance in rat at 0.25 mg/kg, iv | 2013 | European journal of medicinal chemistry, May, Volume: 63 | Synthesis and pharmacokinetic profile of highly deuterated brecanavir analogs. |
| AID743917 | Half life in rat at 0.25 mg/kg, iv | 2013 | European journal of medicinal chemistry, May, Volume: 63 | Synthesis and pharmacokinetic profile of highly deuterated brecanavir analogs. |
| AID743918 | Half life in rat at 0.25 mg/kg, iv co-administered with 4 mg/kg of ritonavir | 2013 | European journal of medicinal chemistry, May, Volume: 63 | Synthesis and pharmacokinetic profile of highly deuterated brecanavir analogs. |
| AID263224 | Antiviral activity against multi PI resistant HIV1 EP14 in MT4 cells | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID743919 | Plasma clearance in rat at 0.25 mg/kg, iv co-administered with 4 mg/kg of ritonavir | 2013 | European journal of medicinal chemistry, May, Volume: 63 | Synthesis and pharmacokinetic profile of highly deuterated brecanavir analogs. |
| AID417048 | Inhibition of human MDR1-dependent accumulation of calcein-AM expressed in MDCK2 cells at 20 uM | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
| Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. |
| AID263218 | Bioavailability in rat at 1 mg/kg co-administered with 4 mg/kg ritonavir | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID328062 | Inhibition of HIV1 protease dimerization in MT2 cells | 2007 | The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
| Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. |
| AID396245 | Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 10% fetal bovine serum by MTS assay | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID263210 | Clearance in rat at 1 mg/kg, iv | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID396234 | Cytotoxicity against human MT4 cells | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID396252 | Ratio of EC50 for HIV1 HXB2 in presence of 20% human serum to EC50 for HIV1 HXB2 in presence of 10% fetal bovine serum | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID396253 | Ratio of EC50 for HIV1 HXB2 in presence of 30% human serum to EC50 for HIV1 HXB2 in presence of 10% fetal bovine serum | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID416857 | Decrease in P-glycoprotein-mediated tenofovir disoproxil fumarate efflux in MDCK2 expressing human MDR1 cells at 20 uM | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
| Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. |
| AID396241 | Cytotoxicity against human IM9 cells | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID263220 | Antiviral activity against amprenavir resistant HIV1 468 in MT4 cells | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID396248 | Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 10% fetal bovine serum and 20% human serum by MTS assay | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID396250 | Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 10% fetal bovine serum and 40% human serum by MTS assay | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID416864 | Inhibition of human MDR1-dependent accumulation of calcein-AM expressed in MDCK2 cells | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
| Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. |
| AID416866 | Effect on tenofovir disoproxil fumarate metabolism in ritonavir booster drug treated healthy human assessed as change in plasma AUC of tenofovir at 300 mg, po, BID co-administered with 300 mg once daily dose of tenofovir disoproxil fumarate | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
| Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. |
| AID328067 | Inhibition of HIV1 protease dimerization in MT2 cells at 1 uM | 2007 | The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
| Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. |
| AID285826 | Tmax in healthy human plasma at 800 mg measured on day 1 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
| Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects. |
| AID396264 | Protein binding in human plasma | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID263211 | Clearance in dog at 1 mg/kg, iv | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID417027 | Effect on tenofovir disoproxil fumarate metabolism in ritonavir booster drug treated healthy human assessed as change in plasma Cmax of tenofovir at 300 mg, po, BID co-administered with 300 mg once daily dose of tenofovir disoproxil fumarate | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
| Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. |
| AID1814286 | Binding affinity to recombinant Cryptococcus neoformans var. grubii H99 major aspartyl peptidase 1 assessed as inhibition constant | 2021 | Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10
| Re-emerging Aspartic Protease Targets: Examining |
| AID328063 | Antiviral activity against HIV1 LAI in MT2 cells | 2007 | The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39
| Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. |
| AID263228 | Displacement of [3H]GW0385 from HIV1 protease | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID396260 | Antiviral activity against HIV1 NL4-3 | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID417047 | Inhibition of esterase mediated-hydrolysis of tenofovir disoproxil fumarate in human intestinal sub cellular fraction S9 at 2 uM after 30 mins | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
| Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. |
| AID396255 | Ratio of EC50 for HIV1 HXB2 in presence of 40% fetal bovine serum to EC50 for HIV1 HXB2 in presence of 10% fetal bovine serum | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID263221 | Antiviral activity against nelfinavir resistant HIV1 14330 in MT4 cells | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID263209 | Antiviral activity against HIV D545701 in MT4 cells | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID396237 | Antiviral activity against HIV1 3B in human PBMC assessed as blockade of reverse transcriptase activity | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID263223 | Antiviral activity against multi PI resistant HIV1 31246 in MT4 cells | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID263213 | Half life in dog at 1 mg/kg | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID285825 | Cmax in healthy human plasma at 800 mg for every 12 hrs measured on day 15 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
| Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects. |
| AID285829 | Apparent oral clearance in healthy human plasma at 800 mg for every 12 hrs measured on day 15 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
| Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects. |
| AID263208 | Antiviral activity against HIV1 EP13 in MT4 cells | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID396242 | Cytotoxicity against human U937 cells | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID396259 | Antiviral activity against HIV1 drug resistant mutant isolates from protease inhibitor treated HIV patient | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID396235 | Antiviral activity against HIV1 3B in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect by MTS assay | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID396258 | Ratio of EC50 for HIV1 HXB2 in presence of 40 mg/ml HSA and 1 mg/ml alpha1-acid glycoprotein to EC50 for HIV1 HXB2 | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID263219 | Bioavailability in dog at 1 mg/kg co-administered with 4 mg/kg ritonavir | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID396240 | Cytotoxicity against human MOLT4 cells | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID263217 | Oral bioavailability in dog at 1 mg/kg | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID285823 | AUC (0-tau) in healthy human plasma at 800 mg for every 12 hrs measured on day 15 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
| Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects. |
| AID396261 | Ratio of EC50 for HIV1 drug resistant mutant isolates from protease inhibitor treated HIV patient to EC50 for drug sensitive HIV1 NL4-3 | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID396243 | Selectivity index, ratio of CCIC50 for human MT4 cells to IC50 for HIV1 3B | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID396246 | Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 40% fetal bovine serum by MTS assay | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID263225 | Antiviral activity against triple multi PI resistant HIV1 in MT4 cells | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID263215 | Half life in dog at 1 mg/kg co-administered with 4 mg/kg ritonavir | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID263216 | Oral bioavailability in rat at 1 mg/kg | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID396247 | Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 10% fetal bovine serum and 10% human serum by MTS assay | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID396251 | Ratio of EC50 for HIV1 HXB2 in presence of 10% human serum to EC50 for HIV1 HXB2 in presence of 10% fetal bovine serum | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID263227 | Antiviral activity against HIV1 I54V in MT4 cells | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID263214 | Half life in rat at 1 mg/kg co-administered with 4 mg/kg ritonavir | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID417037 | Effect on tenofovir disoproxil fumarate metabolism in ritonavir booster drug treated healthy human assessed as change in plasma Cmin of tenofovir at 300 mg, po, BID co-administered with 300 mg once daily dose of tenofovir disoproxil fumarate | 2007 | Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
| Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. |
| AID396239 | Antiviral activity against HIV1 HXB2 in human HeLa cells by HeLa-CD4 MAGI assay | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID263207 | Antiviral activity against HIV1 HXB2 in MT4 cells | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID396249 | Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 10% fetal bovine serum and 30% human serum by MTS assay | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID396262 | Inhibition of HIV1 protease | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID396244 | Antiviral activity against HIV1 HXB2 in human HeLa cells up to 50 uM by HeLa-CD4 MAGI assay | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID285828 | Trough concentration in healthy human plasma at 800 mg for every 12 hrs measured on day 15 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
| Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects. |
| AID743916 | Dose-normalized AUC in rat at 0.25 mg/kg, iv | 2013 | European journal of medicinal chemistry, May, Volume: 63 | Synthesis and pharmacokinetic profile of highly deuterated brecanavir analogs. |
| AID263222 | Antiviral activity against indinavir resistant HIV1 30813 in MT4 cells | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID396254 | Ratio of EC50 for HIV1 HXB2 in presence of 40% human serum to EC50 for HIV1 HXB2 in presence of 10% fetal bovine serum | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID285827 | Tmax in healthy human plasma at 800 mg for every 12 hrs measured on day 15 | 2007 | Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
| Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects. |
| AID263212 | Half life in rat at 1 mg/kg | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID396236 | Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect by MTS assay | 2007 | Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
| In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. |
| AID1795671 | GW0385 Assay from Article 10.1021/bi0488799: \\Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides.\\ | 2004 | Biochemistry, Nov-16, Volume: 43, Issue:45
| Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides. |
| AID1811 | Experimentally measured binding affinity data derived from PDB | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| AID977608 | Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |